The Role of Secondary Surgery in Recurrent Ovarian Cancer | Zendy

Domenica Lorusso | Zendy; Maria Mancini | Zendy; Roberta Di Rocco | Zendy; Rosanna Fontanelli | Zendy; Francesco Raspagliesi | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Role of Secondary Surgery in Recurrent Ovarian Cancer

Author(s) -

Domenica Lorusso,

Maria Mancini,

Roberta Di Rocco,

Rosanna Fontanelli,

Francesco Raspagliesi

Publication year - 2012

Publication title -

international journal of surgical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.432

H-Index - 22

eISSN - 2090-1410

pISSN - 2090-1402

DOI - 10.1155/2012/613980

Subject(s) - medicine , ovarian cancer , disease , cytoreductive surgery , randomized controlled trial , chemotherapy , adjuvant chemotherapy , surgery , cancer , oncology , breast cancer

Despite optimal treatment (complete cytoreduction and adjuvant chemotherapy), 5-year survival for advanced ovarian cancer is approximately 30% and most patients succumb to their disease. Cytoreductive surgery is accepted as a major treatment of primary ovarian cancer but its role in recurrent disease is controversial and remains a field of discussion mainly owing to missing data from prospective randomized trials. A critical review of literature evidence on secondary surgery in recurrent ovarian cancer will be described.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research